The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open label phase 1/2A study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRC253, an androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer.
 
Dana E. Rathkopf
Consulting or Advisory Role - Genentech/Roche; Janssen Oncology; TRACON Pharma
Research Funding - AstraZeneca (Inst); Celgene (Inst); Ferring (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Medivation (Inst); Millennium (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Mansoor N. Saleh
Honoraria - Merck
Speakers' Bureau - Gilead Sciences; Novartis
Research Funding - Aileron Therapeutics (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Incyte (Inst); Lilly (Inst); Sanofi (Inst); TRACON Pharma (Inst)
 
Frank Yung-Chin Tsai
Stock and Other Ownership Interests - Salarius Pharmaceuticals
Consulting or Advisory Role - Tempus
Patents, Royalties, Other Intellectual Property - Clinical trial software.
 
Mehmet Asim Bilen
Consulting or Advisory Role - Exelixis; Nektar; Sanofi
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Incyte (Inst); Nektar (Inst); Peleton (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst)
 
Lee S. Rosen
Research Funding - Bayer (Inst); Lilly (Inst); Pfizer (Inst); PsiOxus Therapeutics (Inst); Regeneron (Inst)
 
Marco Gottardis
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
Patents, Royalties, Other Intellectual Property - Janssen Research & Development
 
Jeffrey R. Infante
Research Funding - Aileron Therapeutics (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Celldex (Inst); Celldex (Inst); eFFECTOR Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Janssen Oncology (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Roche (Inst); Roche (Inst); Tesaro (Inst)
 
Bonne J. Adams
Employment - TRACON Pharma
Stock and Other Ownership Interests - TRACON Pharma
Patents, Royalties, Other Intellectual Property - Tricon Pharmaceuticals
 
Lilian Liu
Employment - TRACON Pharma
Stock and Other Ownership Interests - TRACON Pharma
 
Charles P. Theuer
Employment - TRACON Pharma
Leadership - TRACON Pharma
Stock and Other Ownership Interests - TRACON Pharma
Patents, Royalties, Other Intellectual Property - Tricon Pharmaceuticals
 
James L. Freddo
Leadership - Ignyta
Consulting or Advisory Role - TRACON Pharma
 
Neeraj Agarwal
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; EMD Serono; Exelixis; Foundation One Inc; Genentech/Roche; Lilly; Medivation/Astellas; Merck; Nektar; Novartis; Pfizer; Pharmacyclics
Research Funding - Active Biotech (Inst); Amgen (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Takeda (Inst); TRACON Pharma (Inst)